|
The Immunohistochemistry Antibody Company
|
- Home
-
Products
- All Antibodies
- IHC-plus Antibodies
-
Services
- Immunohistochemistry Studies
- Tissue Cross-Reactivity Screening
- Distributors
-
Resources
- About our Tissue Bank
- Customer Support
- How to Buy
- IHC-plus Protocol
- LSBio Media
- Publications
- Antibody Reports
-
Company
- About LifeSpan
- Press Releases
- Holiday Schedule
- Contact Us
|
|
Bladder Cancer Screen 23 Tissue Microarray - LS-SBLCA23
This tissue microarray is available for use in LSBio Immunohistochemistry Studies only.
|
|
| Catalog ID: |
LS-SBLCA23 |
| Product Name: |
Bladder Cancer Screen 23 |
| Description: |
Bladder cancer with stage/grade and normal/non-neoplastic bladder |
| Format: |
FFPE |
| Category: |
Human Tumor and Normal |
| QA/QC: |
H&E reviewed |
| Storage: |
Short term RT; Long term 4ºC |
| Clinical History: |
No |
| Tissue Marker: |
No |
| Stage/Grade: |
Yes |
| Cases: |
12 |
| Cores: |
24 |
| Slides Per Set: |
1 |
LS-SBLCA23 Tissue Microarray Map
Slide Number 1
| LABEL | | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | | A | Bla | Bla | Bla | Bla | Bla | Bla | Bla | Bla | | B | Bla | Bla | Bla | Bla | Bla | Bla | Bla | Bla | | C | Bla | Bla | Bla | Bla | Bla | Bla | Bla | Bla |
|
Diagnosis Type Legend| Benign non-neoplastic | Diseased | Inflammatory | Malignant | Metastatic | Tumor | Unknown |
Element Tissue LegendBladder (Bla);
LS-SBLCA23 Element Details
| Slide | Position | Species | Gender | Age | Tissue | Diagnosis | Diagnosis Type | TNM Tumor Classification | Tumor Grade | Tumor Stage |
|---|
| 1 | A1 | Human | M | 56 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T2N0M0 | 1 | II |
| 1 | A2 | Human | M | 59 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T1N0M0 | 2 | II |
| 1 | A3 | Human | M | 53 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T3biN0M0 | 2 | III |
| 1 | A4 | Human | F | 52 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T3N0M0 | 3 | II |
| 1 | A5 | Human | M | 56 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T2N0M0 | 1 | II |
| 1 | A6 | Human | M | 59 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T1N0M0 | 2 | II |
| 1 | A7 | Human | M | 53 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T3biN0M0 | 2 | III |
| 1 | A8 | Human | F | 52 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T3N0M0 | 3 | II |
| 1 | B1 | Human | F | 72 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | B2 | Human | M | 50 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T2N0M0 | 3 | II |
| 1 | B3 | Human | M | 74 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T2N0M0 | 3 | II |
| 1 | B4 | Human | M | 48 y | Bladder (Bla) | Adenocarcinoma, Mucinous | Malignant | T2N0M0 | 1 | II |
| 1 | B5 | Human | F | 72 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | B6 | Human | M | 50 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T2N0M0 | 3 | II |
| 1 | B7 | Human | M | 74 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T2N0M0 | 3 | II |
| 1 | B8 | Human | M | 48 y | Bladder (Bla) | Adenocarcinoma, Mucinous | Malignant | T2N0M0 | 1 | II |
| 1 | C1 | Human | M | 71 y | Bladder (Bla) | Adenocarcinoma | Malignant | T3biN0M0 | 2 | III |
| 1 | C2 | Human | M | 51 y | Bladder (Bla) | Carcinoma sarcomatodes | Malignant | T2N0M0 | | II |
| 1 | C3 | Human | F | 40 y | Bladder (Bla) | Normal | Benign non-neoplastic | | | |
| 1 | C4 | Human | F | 40 y | Bladder (Bla) | Normal | Benign non-neoplastic | | | |
| 1 | C5 | Human | M | 71 y | Bladder (Bla) | Adenocarcinoma | Malignant | T3biN0M0 | 2 | III |
| 1 | C6 | Human | M | 51 y | Bladder (Bla) | Carcinoma sarcomatodes | Malignant | T2N0M0 | | II |
| 1 | C7 | Human | F | 40 y | Bladder (Bla) | Normal | Benign non-neoplastic | | | |
| 1 | C8 | Human | F | 40 y | Bladder (Bla) | Normal | Benign non-neoplastic | | | |
Copyright © 2013 LifeSpan BioSciences, Inc. All Rights Reserved
